Brief: Adverum Biotechnologies Reports Fourth Quarter And Full Year 2021 Financial Results
29/03/2022 21:26
March 29 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER AND FULL
YEAR
2021 FINANCIAL RESULTS
* Q4 LOSS PER SHARE $0.35
* ADVERUM BIOTECHNOLOGIES- CASH, CASH EQUIVALENTS,
SHORT-TERM
INVESTMENTS WERE $305.2 MILLION AS OF DEC 31, 2021, COMPARED TO
$332.7 MILLION AS OF SEPT 30, 2021
* ADVERUM BIOTECHNOLOGIES - EXPECTS YEAR-END CASH POSITION
TO
FUND OPERATIONS INTO 2024
Source text for Eikon: ID:nGNX2XWBZx
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)